Can cord blood banks transform into induced pluripotent stem cell banks?

Zhou, Haoming; Rao, Mahendra S.

doi:10.1016/j.jcyt.2015.02.008

Cited by 15 publications

(14 citation statements)

References 35 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given most groups were initially focusing on allogeneic therapy, we initiated a program to generate clinically compliant cells and have reported on the generation of two such lines [ 1 ], which we presume will be used to generate a variety of products from a MCB. Although the process development was expensive and time consuming [ 1 , 14 ], we reasoned that the cost would be amortized over a large number of patients [ 15 ]. Our data suggest that these lines could be used to commercialize iPSC-based cell therapy following a standard Investigational New Drug (IND) path.…”

Section: Introductionmentioning

confidence: 99%

Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications

Baghbaderani

Adhikarla

Sivapatham

et al. 2016

Stem Cell Rev and Rep

Self Cite

View full text Add to dashboard Cite

We have recently described manufacturing of human induced pluripotent stem cells (iPSC) master cell banks (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Reports, 5(4), 647–659, 2015). In this manuscript, we describe the detailed characterization of the two iPSC clones generated using this process, including whole genome sequencing (WGS), microarray, and comparative genomic hybridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibration material and with a reporter subclone and lines made by a similar process from different donors. We believe that iPSCs are likely to be used to make multiple clinical products. We further believe that the lines used as input material will be used at different sites and, given their immortal status, will be used for many years or even decades. Therefore, it will be important to develop assays to monitor the state of the cells and their drift in culture. We suggest that a detailed characterization of the initial status of the cells, a comparison with some calibration material and the development of reporter sublcones will help determine which set of tests will be most useful in monitoring the cells and establishing criteria for discarding a line.Electronic supplementary materialThe online version of this article (doi:10.1007/s12015-016-9662-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications

Baghbaderani

Adhikarla

Sivapatham

et al. 2016

Stem Cell Rev and Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Numerous umbilical cord blood banks have established cord tissue storage programs in anticipation of future potential therapeutic applications of cord tissue derived cells. As has been noted by others, cord blood banks have the required infrastructure in place for donor screening and bio-banking and are familiar with applicable regulatory requirements [36]. Given the practical advantages that cryopreserved cord tissue presents as a source material, further understanding of the therapeutic potential of cord tissue hMSCs in chronic pulmonary diseases is warranted, and may ultimately lead to therapeutic benefit for millions suffering from debilitating disease in the world today.…”

Section: Resultsmentioning

confidence: 99%

Anti-Inflammatory Therapeutic Development and Optimization of Umbilical Cord Tissue Derived Mesenchymal Stem Cells

Sutton¹,

Kaur²,

Brown³

et al. 2018

J Stem Cell Res Ther

View full text Add to dashboard Cite

Inflammation is important in the etio-pathogenesis of pulmonary diseases such as Cystic Fibrosis (CF), bronchoalveolar dysplasia and asthma, often contributing to severe morbidity and mortality. Human Mesenchymal Stem Cells (hMSCs) are known to have anti-inflammatory potential. Umbilical cord tissue is rich in hMSCs, thus making it a feasible option for anti-inflammatory hMSC therapeutic sourcing. Human Cord Tissue (HCT) derived hMSCs were evaluated for their functional potential to treat inflammation, with the hypothesis that HCT hMSCs secrete products that are anti-inflammatory, and that they alter epithelial cell expression of inflammatory properties as well. Further, these studies begin to identify optimized growth conditions to produce the most potent anti-inflammatory effect from the cord tissue derived hMSCs as well as address donor variability in hMSC sourcing. HCT hMSCs cultured with or without Lipopolysaccharide (LPS) or Peptidoglycan (PEP) were analyzed for secreted cytokines using Luminex and for gene expression utilizing RT-PCR and functionality by anti-inflammatory activity on epithelial cell line A549 cells. hMSCs expressed chemokines Interleukin 6 (IL-6), Interleukin 8 (IL-8), Chemokine Ligand 20 (CCL-20), Stem Cell Factor (SCF), and Monocyte Chemoattractant Protein-1 (MCP-1); LPS and PEP enhanced cytokine secretion. hMSCs secreted IL-6, IL-8, Macrophage Inflammatory Protein1-alpha (MIP1a), Tumor Necrosis Factor-alpha (TNF-a) and Interleukin 1-beta (IL-1B); with LPS and PEP stimulation following similar trends. HCT hMSCs showed IL-6 and IL-8 increased expression in functionality assay, which could be altered for optimization through changes in media glucose concentration. hMSCs secrete a variety of cytokines and display anti-inflammatory activity, with growth medium and donor variability. Optimization of HCT through growth medium as well as donor sourcing may be important for the development of disease specific therapeutics, but ultimately holds promise as a rich source for hMSCs.

show abstract

“…These banks could adopt several models for matching haplotypes of human leukocyte antigens (HLAs), which are described briefly below. [30][31][32][33] One model would account for patientspecific iPS cells, which would be expected to have only the relatively weak antigenicity that was detailed in the previous section. While providing the best HLA match to the patient, this method suffers from the late onset for therapy development.…”

Section: Psc Bankingmentioning

confidence: 99%